• Explore /
  • Poster
  • / Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.

Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.

Abstract Poster

Authors

Michael Morris

Michael J. Morris

Memorial Sloan Kettering Cancer Center, New York, NY

Michael J. Morris , Celestia S. Higano , Howard I. Scher , Christopher Sweeney , Emmanuel S. Antonarakis , Daniel H. Shevrin , Charles J. Ryan , Yohann Loriot , Karim Fizazi , Neeta Pandit-Taskar , Jose E. Garcia-Vargas , Kari Lyseng , Marianne Bloma , Jorge A. Carrasquillo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01106352

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5012)

DOI

10.1200/jco.2015.33.15_suppl.5012

Abstract #

5012

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Michael J. Morris

First Author: Michael J. Morris

First Author: Esmail M. Al-Ezzi

First Author: Jae Young Joung